In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash
Journal of the European Academy of Dermatology and Venereology · 2025-08 · 39 (8)
DOI: 10.1111/jdv.20719 ↗At a glance
Leserbrief in Journal of the European Academy of Dermatology and Venereology, published online on 2025-05-06. Written by Azael Freites-Martinez and 2 co-authors. Institution: Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain. 10 references.
Abstract (original language)
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Authors and institutions
- Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain.
- First Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France.
ORCID profiles: Azael Freites-Martinez, Zoe Apalla, Vincent Sibaud
Cite
APA
Freites-Martinez, A., Apalla, Z., & Sibaud, V. (2025). In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology, 39(8). https://doi.org/10.1111/jdv.20719
Vancouver
Freites-Martinez A, Apalla Z, Sibaud V. In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology. 2025;39(8). doi:10.1111/jdv.20719
BibTeX
@article{FreitesMartinez2025,
author = {Freites-Martinez, Azael and Apalla, Zoe and Sibaud, Vincent},
title = {In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {8},
doi = {10.1111/jdv.20719}
}
EUVIMED